TV News LIES

Tuesday, Sep 02nd

Last update01:41:00 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Doctors strike as Ebola epidemic spirals

Liberia doctors strikeDoctors in Liberia were out on strike on Tuesday as they struggled to cope with the...

Study: Novel heart failure drug shows big promise

NovartisA new study reports one of the biggest potential advances against heart failure in more than...

Louisiana Abortion Law Temporarily Blocked

Loouisiana bortion law blockedA federal judge on Sunday temporarily blocked a Louisiana law that advocates say would likely have...

Fracking Link to Birth Defects Probed in Early Research

Fracking linked to birth defectsThe first research into the effects of oil and gas development on babies born near wells...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!